ESPE Yearbook of Paediatric Endocrinology

ESPE Yearbook of Paediatric Endocrinology

ISSN 1662-4009 (online)

Published by BioScientifica

Page 1 of about 2 results

ey0019.15-1 | Obesity | ESPEYB19

15.1. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

JP Frias , MJ Davies , J Rosenstock , FC Perez Manghi , L Fernandez Lando , BK Bergman , B Liu , X Cui , K Brown , SURPASS-2 Investigators

N Engl J Med. 2021;385(6):503-15. doi: 10.1056/NEJMoa2107519.PubMed ID: 34170647Brief summary: this randomized control trial in 1879 adults with type 2 diabetes compared effects of once-weekly Tirzepatide (5, 10 or 15 mg) versus once-weekly Semaglutide (1 mg) on glycemic control. After 40 weeks, all doses of Tirzepatide were superior to Semaglutide on lowering HbA1c.Gluca...
0 shares

ey0017.14-9 | (1) | ESPEYB17

14.9. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

SA Harrison , MR Bashir , CD Guy , R Zhou , CA Moylan , JP Frias , N Alkhouri , MB Bansal , S Baum , BA Neuschwander-Tetri , R Taub , SE Moussa

To read the full abstract: Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6.Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist. This 36-week long randomised, placebo-controlled trial in 348 US adults with biopsy confirmed non-alcoholic steatohepatitis (fibrosis stages 1–3) shows that Resmetirom...
0 shares

Published by BioScientifica

ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more